Toronto Dominion Bank Purchases 33,718 Shares of Zoetis Inc. (ZTS)
Toronto Dominion Bank boosted its position in Zoetis Inc. (NYSE:ZTS) by 25.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 166,276 shares of the company’s stock after purchasing an additional 33,718 shares during the quarter. Toronto Dominion Bank’s holdings in Zoetis were worth $10,370,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Zoetis by 3.9% in the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after purchasing an additional 1,412,829 shares during the period. Vanguard Group Inc. boosted its stake in Zoetis by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after purchasing an additional 910,265 shares during the period. State Street Corp boosted its stake in Zoetis by 4.9% in the 1st quarter. State Street Corp now owns 21,256,557 shares of the company’s stock valued at $1,134,453,000 after purchasing an additional 986,680 shares during the period. Morgan Stanley boosted its stake in Zoetis by 182.5% in the 1st quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after purchasing an additional 9,442,207 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in Zoetis by 55.4% in the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after purchasing an additional 3,695,449 shares during the period. Institutional investors and hedge funds own 93.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Toronto Dominion Bank Purchases 33,718 Shares of Zoetis Inc. (ZTS)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/17/toronto-dominion-bank-purchases-33718-shares-of-zoetis-inc-zts.html.
Several research firms recently issued reports on ZTS. BidaskClub upgraded Zoetis from a “sell” rating to a “hold” rating in a research note on Friday. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Thursday, October 12th. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research note on Tuesday, September 26th. Stifel Nicolaus restated a “buy” rating and issued a $65.00 price target on shares of Zoetis in a research note on Friday, September 1st. Finally, Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the company a “buy” rating in a research note on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company’s stock. Zoetis has a consensus rating of “Buy” and an average target price of $65.76.
Zoetis Inc. (NYSE:ZTS) traded up 0.44% during trading on Tuesday, hitting $66.00. The stock had a trading volume of 458,351 shares. The stock has a market capitalization of $32.28 billion, a P/E ratio of 37.31 and a beta of 1.02. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $66.11. The company has a 50-day moving average of $63.94 and a 200-day moving average of $60.97.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.49 earnings per share. On average, equities analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a yield of 0.64%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio is 23.73%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.